{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-026438","form_type":"8-K","ticker":"VVOS","cik":"0001716166","company_name":"Vivos Therapeutics, Inc.","filed_at":"2025-12-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.241858+00:00","generated_at":"2026-05-16T14:16:51.678518+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vivos Therapeutics issues $2.09M unsecured note, net proceeds $1.5M, weekly $70K payments","bullets":["Principal amount $2,093,340; net proceeds ~$1,500,000 after $587,340 OID and $6,000 fees.","Weekly payments of $69,778 start December 12, 2025; full prepay by Jan 4, 2026 reduces balance by $286,140.","Note is unsecured, no interest unless default; subsidiary Airway Integrated Management guarantees obligations.","Proceeds for working capital and general corporate purposes; no placement agent used.","Lender Avondale Capital is affiliate of Streeterville Capital (prior senior secured loan from June 2025)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-026438","json":"https://secwatch.observer/filing/0001493152-25-026438.json","markdown":"https://secwatch.observer/filing/0001493152-25-026438.md","text":"https://secwatch.observer/filing/0001493152-25-026438.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716166/000149315225026438/0001493152-25-026438-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716166/000149315225026438/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T14:16:51.678518+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cc1da529dd811b581bd2abd48005457df66feeb9","claim":"Vivos Therapeutics, Inc. incurred loan of $2,093,340 with Avondale Capital, LLC at does not bear interest maturing not stated.","evidence_excerpt":"On December 5, 2025, Vivos Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into a Note Purchase Agreement (the “ Note Purchase Agreement ”) with from Avondale Capital, LLC, a Utah limited liability company (“ Lender ”), pursuant to which the Company issued and sold to Lender a Promissory Note (the “ Note ”) in the original principal amount of $2,093,340","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315225026438/0001493152-25-026438-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$2,093,340"},{"label":"Counterparty","value":"Avondale Capital, LLC"},{"label":"Rate","value":"does not bear interest"},{"label":"Maturity","value":"not stated"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}